Lamivudine

拉米夫定

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameLamivudine
Drug Alias Namelamivudinum拉美芙锭lamivudina拉米芙定拉夫米定 +[18] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsPolyarteritis NodosaGlomerulonephritisRetinal Detachment +[9] 
Global Approved IndicationsHepatitis BHIV Infections
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritoryUnited States
Original Approved Date1995/11/17
Country/TerritoryZambiaUnited StatesUnited Kingdom +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979UT Health San AntonioGlaxosmithkline Plc +[9] 
Inactive CompaniesKirby InstituteUniversity Of Wisconsin-MadisonFudan University +[5] 
Active IndicationsAlzheimer DiseaseHepatitis B, ChronicHepatitis B +[4] 
Inactive IndicationsPolyarteritis NodosaGlomerulonephritisRetinal Detachment +[5] 

Other Information

ATC CodeJ05AF05
Related LinksWikipediaDrugBankKEGG